UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| ITEM 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
(d) On September 9, 2020, the Board of Directors (the “Board”) of Myriad Genetics, Inc. (“Myriad”) approved an increase in the size of the Board from eleven to twelve members and appointed Rashmi Kumar to fill the newly created vacancy, effective immediately, to serve as a Class III Director with a term expiring at Myriad’s 2020 Annual Meeting of Stockholders. The Board has determined that Ms. Kumar meets the independence requirements of the Securities and Exchange Commission and the Nasdaq Stock Market Rules. The Board appointed Ms. Kumar to serve on the Audit and Finance Committee of the Board, effective immediately.
Ms. Kumar will be compensated for her service as director on the same basis as other non-employee directors of Myriad, as more fully described in the “Director Compensation” section of Myriad’s definitive proxy statement for the 2019 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on October 16, 2019. Pursuant to Myriad’s non-employee director compensation policy, in connection with her appointment to the Board, Ms. Kumar will be granted a restricted stock unit award for shares of Myriad’s common stock having an aggregate value of $300,000. The foregoing grant will vest one year following the grant date. Ms. Kumar will also enter into Myriad’s standard indemnification agreement for directors and executive officers.
There are no arrangements or understandings between Ms. Kumar and any other person pursuant to which she was selected to serve on the Board, and Ms. Kumar is not party to any related party transactions required to be reported pursuant to Item 404(a) of Regulation S-K.
On September 10, 2020, Myriad issued a press release announcing Ms. Kumar’s appointment to the Board, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1.
| ITEM 9.01 | Financial Statements and Exhibits. |
| Exhibit Number |
Description | |
| 99.1 | Press Release, dated September 10, 2020. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
The exhibit(s) may contain hypertext links to information on our website or other parties’ websites. The information on our website and other parties’ websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MYRIAD GENETICS, INC. | ||||||
| Date: September 10, 2020 | By: | /s/ R. Bryan Riggsbee | ||||
| R. Bryan Riggsbee | ||||||
| Executive Vice President, Chief Financial Officer | ||||||